European Academy of Dermatology and Venereology (EADV) 35th Congress

Ruxolitinib cream improves repigmentation in patients with vitiligo

Elaine Soliven, 20211109000000

The application of ruxolitinib cream led to significant improvements in facial and total body repigmentation among adolescents and adults with vitiligo, according to two phase III studies presented at EADV 2021.

Ritlecitinib prevents hair loss in patchy baldness

Novel JAK3 blocker: Potential to stave off balding?

Pearl Toh, 20211022140100

The oral selective Janus kinase 3 (JAK3) inhibitor ritlecitinib effectively prevents hair loss in people with alopecia areata (AA) compared with placebo, according to the ALLEGRO study presented at EADV 2021.

Bimekizumab maintains skin clearance in patients with plaque psoriasis

Elaine Soliven, 20211022000000

Maintenance treatment with bimekizumab achieves complete scalp, palmoplantar, or nail clearance in patients with moderate-to-severe plaque psoriasis, according to two phase III trials presented at EADV 2021.

Roflumilast cream eases itch severity in chronic plaque psoriasis

Roflumilast cream eases itch burden, severity in chronic plaque psoriasis

Roshini Claire Anthony, 20211019180001

In patients with chronic plaque psoriasis, once-daily treatment with roflumilast improved severity and burden of itch compared with vehicle cream, according to results of the phase III DERMIS-1 and DERMIS-2 trials presented at EADV 2021.

Tapinarof a new kid on the block for plaque psoriasis

Elvira Manzano, 20211018000000

Treatment with the nonsteroidal topical cream tapinarof 1% for up to 52 weeks helps control plaque psoriasis in the phase III PSOARING 3 trial.

Abrocitinib trumps dupilumab for itch relief in AD

Abrocitinib trumps dupilumab for itch relief in eczema

Pearl Toh, 20211016140100

The oral selective JAK*1 inhibitor abrocitinib is superior to dupilumab for relieving itch and achieving skin clearance in people with moderate-to-severe atopic dermatitis (AD), according to results from a head-to-head comparison in the JADE DARE trial presented at EADV 2021.

Baricitinib: A potential treatment for alopecia areata?

Roshini Claire Anthony, 20211014180001

Baricitinib, an oral, selective Janus kinase (JAK)1/JAK2 inhibitor, may help improve hair growth in patients with severe alopecia areata, according to results from the phase III BRAVE-AA1 and BRAVE-AA2 trials.

Secukinumab: Fewer jabs do the job in psoriasis

Elvira Manzano, 20211012000000

New data presented at EADV 2021 support the efficacy of secukinumab 300-mg dose in a 2-mL autoinjector compared with two 150 mg in 1 mL pre-filled syringes or placebo for psoriasis, with no new safety signals observed within 52 weeks.

POETYK trials highlight potential of novel drug for plaque psoriasis

Audrey Abella, 20211011100000

The investigational, first-in-class, allosteric tyrosine kinase 2 (TYK2) inhibitor deucravacitinib showed durable efficacy for the treatment of moderate-to-severe plaque psoriasis*, according to the 52-week efficacy analysis results of the POETYK** PSO-1 and POETYK PSO-2 trials presented at EADV 2021.

Long-term KEEPsAKE data show sustained improvements with risankizumab for PsA

Audrey Abella, 20211008100000

The humanized immunoglobulin G1 monoclonal antibody risankizumab conferred long-term benefit for individuals with active psoriatic arthritis (PsA) who had inadequate responses to biologic and conventional synthetic DMARDs* (csDMARDs), according to the open-label extension (OLE) phase findings of the KEEPsAKE 1 and 2 trials presented at EADV 2021.